AMEERA-5: A Randomized, Double-Blind Phase III Study of Amcenestrant + Palbociclib vs Letrozole + Palbociclib for Previously Untreated ER+/HER2- Advanced Breast Cancer

home / investigator-perspectives / ameera-5-a-randomized-double-blind-phase-iii-study-of-amcenestrant-palbociclib-vs-letrozole-palb

Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.

EP. 1: Understanding the Scope of ER+ Breast Cancer

Sara A. Hurvitz, MD

June 30th 2021

Sara Hurvitz, MD, provides an overview of HR+ breast cancer.

Watch

EP. 2: Treatment Options For Advanced ER+ Breast Cancer

Sara A. Hurvitz, MD

June 30th 2021

Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.

Watch

EP. 3: Safety and Efficacy of Amcenestrant in the AMEERA Trials

Sara A. Hurvitz, MD

June 30th 2021

Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.

Watch

EP. 4: AMEERA-5: Key Data and Implications for Practice

Sara A. Hurvitz, MD

June 30th 2021

An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.

Watch

EP. 5: Potential Role for Amcenestrant in the Treatment of ER+/HER2- Advanced Breast Cancer

Sara A. Hurvitz, MD

June 30th 2021

Sara Hurvitz, MD, provides insight on the potential role of amcenestrant in the treatment of HR+ breast cancer in the future.

Watch